VBI Vaccines announces completion of enrollment in PROTECT phase 3 clinical study
VBI Vaccines announced completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation hepatitis B vaccine. More than 1,600 adults have now been enrolled in the PROTECT study at 27 sites. April 19, 2018